Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Lothar Leimer"'
Autor:
Nicola Gökbuget, Christina-Maria Hartog, Renato Bassan, Heinz-Gerd Derigs, Herve Dombret, Richard Greil, Jesus-Maria Hernández-Rivas, Francoise Huguet, Tamara Intermesoli, Eric Jourdan, Christian Junghanss, Lothar Leimer, Maria-Jose Moreno, Albrecht Reichle, Josep Ribera, Matthias Schmid, Hubert Serve, Matthias Stelljes, Reingard Stuhlmann, Dieter Hoelzer
Publikováno v:
Haematologica, Vol 96, Iss 2 (2011)
Background Treatment of central nervous system relapse in adult acute lymphoblastic leukemia is a challenge and outcome is poor. Liposomal cytarabine has a prolonged half-life and, given intrathecally, has produced high response rates in patients wit
Externí odkaz:
https://doaj.org/article/c06780166d684e64a9f8dc634b313cbc
Autor:
Knut Wendelin, Markus Schaich, Christian Junghanss, Anthony D. Ho, Kerstin Schaefer-Eckart, Hannes Wandt, Ulrich Mahlknecht, Gerhard Ehninger, Mathias Hänel, Lothar Leimer, Michael Kramer, Martin Wilhelm, Regina Herbst, Rainer Schwerdtfeger, Gottfried Dölken, Bettina Pilz, Martin Kaufmann, Anne Friederike Klenner, Markus Thalheimer, Roland Conradi
Publikováno v:
The Lancet. 380:1309-1316
Summary Background Routine prophylactic platelet transfusion is the standard of care for patients with severe thrombocytopenia. We assessed the effect of a new strategy of therapeutic platelet transfusion on the number of transfusions and safety in p
Autor:
Heinz-Gerd Derigs, Nicola Gökbuget, María-José Moreno, Lothar Leimer, Christian Junghanss, Renato Bassan, Tamara Intermesoli, Richard Greil, Matthias Schmid, Albrecht Reichle, Josep M. Ribera, Jesús María Hernández-Rivas, Reingard Stuhlmann, Françoise Huguet, Hubert Serve, Christina-Maria Hartog, Eric Jourdan, Hervé Dombret, Dieter Hoelzer, Matthias Stelljes
Publikováno v:
Haematologica. 96:238-244
Background Treatment of central nervous system relapse in adult acute lymphoblastic leukemia is a challenge and outcome is poor. Liposomal cytarabine has a prolonged half-life and, given intrathecally, has produced high response rates in patients wit
Autor:
Heike Pfeifer, Urban J. Scheuring, Lothar Leimer, A Käbisch, Dieter Hoelzer, Oliver G. Ottmann, Anja Binckebanck, Michael Lübbert, Harald Gschaidmeier, Barbara Wassmann
Publikováno v:
Leukemia. 17:1919-1924
Imatinib has marked antileukemic activity in advanced Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL), but secondary resistance develops rapidly, reflecting the limitations of single-agent therapy. Experimental data suggest tha
Autor:
Heike, Pfeifer, Barbara, Wassmann, Wolf-Karsten, Hofmann, Martina, Komor, Urban, Scheuring, Patrick, Brück, Anja, Binckebanck, Eberhard, Schleyer, Nicola, Gökbuget, Thomas, Wolff, Michael, Lübbert, Lothar, Leimer, Harald, Gschaidmeier, Dieter, Hoelzer, Oliver G, Ottmann
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 9(13)
In patients with acute leukemias, a lymphoid phenotype, the presence of a Philadelphia chromosome (Ph), and inadequate central nervous system (CNS)-directed prophylactic therapy are risk factors for CNS involvement. Imatinib mesylate has promising si
Autor:
Dieter Hoelzer, Harald Rieder, Oliver G. Ottmann, Gerhard Ehninger, Patrick Brück, Barbara Wassmann, Heike Pfeifer, Urban J. Scheuring, Thomas Lipp, Johannes Atta, Matthias Stelljes, Lothar Leimer, Harald Gschaidmeier, Claudia Schoch, Jolanta B. Perz, Nicola Gökbuget, Rainer Schwerdtfeger, Anja Binckebanck
Publikováno v:
Blood. 103(4)
Imatinib has pronounced but brief antileukemic activity in advanced Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ALL). We assessed the prognostic impact of pretreatment disease features and the early bone marrow (BM) response i
Autor:
Elke Jäger, Kai U. Chow, Annette Meyer, Lothar Leimer, Paris S. Mitrou, H. D. Peters, Mathias J. Rummel, Martin L. Hansmann, Deter K. Hossfeld, Lothar Bergmann, Dieter Hoelzer
Publikováno v:
Leukemialymphoma. 35(1-2)
Aim of this multicenter-study was to evaluate rate and duration of remissions and to examine toxicity of cladribine in low-grade lymphomas as first-line therapy or in first relapse using intermittent 2-hour-infusion of cladribine. A total of 294 cour
Autor:
Winfried Gassmann, Andreas Käbisch, Sylvia Wystub, Anja Binckebanck, Michael Lübbert, Patrick Brueck, Heike Pfeifer, Oliver G. Ottmann, Aristoteles Giagounidis, Lothar Leimer, Dieter Hoelzer, Hubert Serve, Barbara Wassmann
Publikováno v:
Blood. 120:1503-1503
Abstract 1503 Background: The frequent development of acquired resistance in patients with Ph+ALL initially responsive to tyrosine kinase inhibitor(TKI)-based regimens highlights the need for more effective post-remission therapy. Imatinib or dasatin
Autor:
Heike Pfeifer, Andreas Hüttmann, Julanta Dengler, Lothar Leimer, Anke Morgner, Karl-Anton Kreuzer, Diana Ditz, Reingard Stuhlmann, Barbara Wassmann, Anja Binckebanck, Michael Lübbert, Matthias Stelljes, Mathias Schmid, Hans-Walter Lindemann, Nicola Goekbuget, Thomas Burmeister, Joachim Beck, Christian Völp, Kerstin Schäfer-Eckart, Dieter Hoelzer, Markus Schaich, Theis H. Terwey, Oliver G. Ottmann, Karsten Spiekermann
Publikováno v:
Blood. 116:173-173
Abstract 173 Imatinib (IM) in combination with either of a variety of chemotherapy regimens has become the mainstay of front-line treatment for younger patients with Ph+ ALL, followed by allogeneic SCT as a curative treatment option. Complete remissi
Autor:
Reingard Stuhlmann, Andreas Huettmann, Lothar Leimer, Albrecht Reichle, Hubert Serve, Nicola Goekbuget, Theis H. Terwey, Kerstin Schaefer-Eckart, Stefan Zewen, Helmut Diedrich, Mathias Schmid, Dieter Hoelzer, Anja Baumann, Joachim Beck, Marc Schmalzing, Martin Mohren, Monika Brueggemann, Markus Schaich
Publikováno v:
Blood. 116:494-494
Abstract 494 Several randomised pediatric trials have demonstrated that intensification of Asparaginase (ASP) treatment in ALL can contribute to improved outcome. In adult ALL few data are availabe and optimal ASP preparation, schedule and intensity